http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2009286276-A1
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_94963c8f0b38c247a11b8fc4510dee16 http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_8b6c3d507ad6a41ee2db70a1cda25307 http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_c579a703c5d59a914955e4f87b216fd7 http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_88a6978b576184a579d50d2ec64b9ee8 |
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2800-52 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2333-485 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-5011 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-574 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12Q1-02 |
| filingDate | 2009-05-14-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_f0596c5128c160d6491328eaa30796f3 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_54607a70cc05da4ea53ce26cc965d3b0 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_68531f056f4087bafb0faa2a06f1146a http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_da5f49a691e7134c03bc3d9728ec4e11 |
| publicationDate | 2009-11-19-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | US-2009286276-A1 |
| titleOfInvention | Methods for predicting a patient's response to egfr inhibitors |
| abstract | The present invention provides methods for individualizing chemotherapy for cancer treatment, and particularly for evaluating a patient's responsiveness to one or more epidermal growth factor receptor (EGFR) inhibitors prior to treatment with such agents. Particularly, the invention provides an in vitro chemoresponse assay for predicting a patient's response to an EGFR inhibitor, such as an EGFR tyrosine kinase inhibitor or a molecule targeting the extracellular domain of EGFR. The method generally comprises culturing malignant cells from a patient's specimen (e.g., biopsy specimen), contacting the cultured cells with an EGFR inhibitor that is a candidate treatment for the patient, and evaluating the cultured cells for a response to the drug. In certain embodiments, monolayer(s) of malignant cells are cultured from explants prepared by mincing tumor tissue, and the cells of the monolayer are suspended and plated for chemosenstivity testing. The in vitro response to the drug as determined by the method of the invention is correlative with the patient's in vivo response upon receiving the EGFR inhibitor during chemotherapeutic treatment (e.g., in combination with other standardized or individualized chemotherapeutic regimen). |
| isCitedBy | http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2011130302-A1 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2014133950-A1 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2010216168-A1 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2011068841-A1 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2011238322-A1 |
| priorityDate | 2008-05-14-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 122.